Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression

Milad Ashrafizadeh; Sepideh Mirzaei; Mohammad Hossein Gholami; Farid Hashemi; Amirhossein Zabolian; Mehdi Raei; Kiavash Hushmandi; Ali Zarrabi; Nicolas H Voelcker; Amir Reza Aref; Michael R Hamblin; Rajender S Varma; Saeed Samarghandian; I J Arostegi; M Alzola; Alan Prem Kumar; Vijay Kumar Thakur; Noushin Nabavi; Pooyan Makvandi; Franklin R Tay; Gorka Orive

doi:10.1016/j.carbpol.2021.118491

Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression

Carbohydr Polym. 2021 Nov 15:272:118491. doi: 10.1016/j.carbpol.2021.118491. Epub 2021 Jul 27.

Authors

Milad Ashrafizadeh¹, Sepideh Mirzaei², Mohammad Hossein Gholami³, Farid Hashemi⁴, Amirhossein Zabolian⁵, Mehdi Raei⁶, Kiavash Hushmandi⁷, Ali Zarrabi⁸, Nicolas H Voelcker⁹, Amir Reza Aref¹⁰, Michael R Hamblin¹¹, Rajender S Varma¹², Saeed Samarghandian¹³, I J Arostegi¹⁴, M Alzola¹⁴, Alan Prem Kumar¹⁵, Vijay Kumar Thakur¹⁶, Noushin Nabavi¹⁷, Pooyan Makvandi¹⁸, Franklin R Tay¹⁹, Gorka Orive²⁰

Affiliations

¹ Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanlı, Tuzla, 34956, Istanbul, Turkey; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, 34956, Istanbul, Turkey.
² Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran.
³ Faculty of Veterinary Medicine, Kazerun Branch, Islamic Azad University, Kazerun, Iran.
⁴ Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
⁵ Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
⁶ Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
⁷ Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
⁸ Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, 34956, Istanbul, Turkey.
⁹ Monash Institute of Pharmaceutical Sciences, Parkville, Victoria 3052, Australia; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Clayton, Victoria, 3168, Australia; Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, 151 Wellington Road, Clayton, Victoria 3168, Australia.
¹⁰ Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Translational Sciences, Xsphera Biosciences Inc., Boston, MA, USA.
¹¹ Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa; Radiobiology Research Center, Iran University of Medical Science, Tehran, Iran.
¹² Regional Center of Advanced Technologies and Materials, Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic.
¹³ Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
¹⁴ NanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain.
¹⁵ NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore; Cancer Science Institute of Singapore and Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.
¹⁶ Biorefining and Advanced Materials Research Center, Scotland's Rural College (SRUC), Kings Buildings, Edinburgh EH9 3JG, UK; Department of Mechanical Engineering, School of Engineering, Shiv Nadar University, Uttar Pradesh 201314, India.
¹⁷ Department of Urological Sciences and Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V6H3Z6, Canada.
¹⁸ Istituto Italiano di Tecnologia, Center for Materials Interfaces, viale Rinaldo Piaggio 34, 56025 Pontedera, Pisa, Italy. Electronic address: Pooyan.makvandi@iit.it.
¹⁹ The Graduate School, Augusta University, Augusta, GA, USA. Electronic address: ftay@augusta.edu.
²⁰ NanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain; University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria-Gasteiz, Spain; Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz, Spain; Singapore Eye Research Institute, The Academia, 20 College Road, Discovery Tower, Singapore. Electronic address: gorka.orive@ehu.eus.

PMID: 34420747
DOI: 10.1016/j.carbpol.2021.118491

Abstract

An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor-mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.

Keywords: CD44; Doxorubicin; Drug resistance; Endocytosis; Hyaluronic acid; Nanodelivery system; Theranostic.

Publication types

Review

MeSH terms

Animals
Doxorubicin* / administration & dosage
Doxorubicin* / chemistry
Doxorubicin* / pharmacology
Drug Carriers* / chemistry
Drug Delivery Systems / methods
Drug Resistance, Neoplasm* / drug effects
Humans
Hyaluronic Acid* / chemistry
Nanoparticles / chemistry
Neoplasms* / drug therapy

Substances

Hyaluronic Acid
Doxorubicin
Drug Carriers